Predicting response to therapy of squamous cell carcinoma of the head and neck

Anticancer Research

Volumn 16, Issue 4 C, 1996, Pages 2389-2396

  Wennerberg, Johan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carcinoma; Head and neck neoplasms; Prediction; Squamous cell; Therapy

Indexed keywords

COMPLEMENT COMPONENT C1Q;

ARTICLE; CANCER STAGING; HEAD AND NECK TUMOR; HUMAN; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT PLANNING;

CARCINOMA, SQUAMOUS CELL; CELL DIVISION; HEAD AND NECK NEOPLASMS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029791563     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Bryne, M. Prognostic value of various molecular and cellular features in oral squamous cell carcinomas: a review. J Oral Pathol Med 20: 413-420, 1991.
2. Eddy, D. M. Principles for making difficult decisions in difficult times. JAMA 271: 1792-8, 1994.
3. Peters LJ: Through a glass darkly: Predicting the future of radiation oncology. Int J Radiat Oncol Biol Phys 31: 219-25, 1994.
4. Bailey BJ: Beyond the "new" TNM classification. Arch Otolaryngol Head Neck Surg. 117: 369-370, 1991.
5. Dreyfuss AI and R CJ: Analysis of prognostic factors in squamous cell carcinomas of the head and neck. Hematol/Oncol Clin North Am 5: 701-712, 1991.
6. Kearsley JH and Thomas S: Prognostic markers in cancers of the head and neck. Anti-Cancer Drugs 4: 419-429, 1993.
7. Carter, R. Pathology of squamous carcinomas of the head and neck. Curr Opin in Oncol 4: 485-490, 1992.
8. Schantz SP: Carcinogenesis, markers, staging, and prognosis of head and neck cancer. Curr Opin Oncol 5: 483-490, 1993.
9. Inki P, Joensuu H, Grenman R, Klemi P and Jalkanen M: Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 70: 319-323, 1994.
10. Zeillinger R, Swoboda H, Machacek E, Nekahm D, Sliutz G, Knogler W, Speiser P, Swoboda E and Kubista E: Expression of cathepsin D in head and neck cancer. Eur J Cancer 28A: 1413-1415, 1992.
11. Gasparini G, Pozza F and Harris AL: Evaluating the potential useful lness of new prognostic and predictive indicators in node-negative breast cancer patients. J Nat Cancer Inst 85: 1206-1219, 1993.
12. Peters LJ: Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiotherapy and Oncology 17: 177-190, 1990.
13. Brennan CT, Sessions DG, Spitznagel EL and Harvey LE: Surgical pathology of cancer of the oral cavity and oropharynx. Laryngoscope 101: 1175-97, 1991.
14. Huang DT, Johnson CR, Schmidt-Ullrich R and Grimes M: Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study. Int J Radiation Oncology Biol Phys 23: 737-42, 1992.
15. Weaver A, Fleming S, Ensley J, Kish JA, Jacobs J, Kinzie J, Crissman J and Al-Sarraf M: Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-flurouracil before definitive therapy for locally advanced head and neck cancer. Amer J Surgery 148: 525-529, 1984.
16. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J and Al-Sarraf M: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hours 5-FU infusion and cisplatin. Cancer 55: 1123-1128, 1985.
17. Haas JS, Toohill RJ, Haas CD, Wilson JF, Byhardt RW, Ritch PC, and Grossman TW: The effect of delaying standard treatment for induction chemotherapy in advanced head and neck cancer. Am J Clin Oncol (CCT) 10: 116, 1987.
18. Stell PM and Rawson NSB: Adjuvant chemotherapy in head and neck cancer. Br J Cancer 61: 779-787, 1990.
19. Veterans Affairs Laryngcal Cancer Study Group Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. New England J Medicine 124: 1685-1690, 1991.
20. Forastiere, A. A. Randomized trials of induction chemotherapy. A critical review. Haematol/Oncol Clin North Am 5: 725-736, 1991.
21. Jacobs C and Makuch R: Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the head and neck contracts program. J Gin Oncol 8: 838-847, 1990.
22. Rosenthal DI, Pistenmaa DA and Glatstein E: A review of neoadjuvant chemotherapy for head and neck cancer: Partially shrunken tumors may be both leaner and meaner. Int J Radiation Oncology Biol Phys 28: 315-320, 1994.
23. Ensley J, Maciorowski Z, Pietraszkiewicz H et al Methodology and clinical applications of flow cytometry in squamous cell carcinomas of the head and neck. In Jacobs C, ed. Carcinomas of the Head and Neck, Evaluation and Management Boston: Kluwer Academic Publishers, 225-242, 1990.
24. Cooke LD, Cooke TG, Bootz F, Forster G, Helliwell TR, Spiller D, and Stell PM: Ploidy as a prognostic indicator in end stage squamous cell carcinoma of the head and neck region treated with cisplatinum. Br J Cancer 61: 759-762, 1990.
25. Gregg CM, Beals TE, McClatchy KM, Fisher SG and Wolf GT: DNA content and tumor response to induction chemotherapy in patients with advanced laryngeal squamous cell carcinoma. Otolaryngology - Head and Neck Surgery 108: 731-737, 1993.
26. Tennvall J, Wennerberg J, Anderson H, Baldetorp B, Fernö M and Willén R: DNA analysis as a predictor of the outcome of induction chemotherapy in advanced head and neck carcinomas. Archives of Otolaryngology - Head and Neck Surgery 119: 867-870, 1993.
27. Segalin A, Ruol A, Panozzo M, Bonavina L, Blanchi LC and Peracchia A: Flow cytometric DNA analysis does not predict the radiochemoresponsiveness of oesophageal cancer. J Surg Oncol 54: 87-90, 1993.
28. Schantz SP, Savage HE, Brown BW, Reuben JM, Hong WK and Rossen RD: Association of levels of circulating C1q binding macromolecules with induction chemotherapy response in head and neck cancer patients. Cancer Res 48: 5868-5873, 1988.
29. Schantz SP, Savage HE, Racz T, Liu FJ, Brown BW, Rossen RD and Hong WK: Immunologic determinants of head and neck cancer response to induction therapy. J Clin Oncol 7: 857-864, 1989.
30. Schantz SP, Savage HE, Brown BW, Young G, Liu FJ, Reger G and Newman RA: Significance of C1q-binding macromolecules within the head and neck cancer patient. Cancer Res 50: 4349-4354, 1990.
31. Mattern J and Volm M: Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treatm Rev 9: 267-298, 1982.
32. Hamburger AW and Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461-463, 1977.
33. Hamburger AW, Salmon SE, Kim MB Trent JM, Soehnlein BJ, Alberts DS and Schmidt HJ: Direct cloning of human ovarian carcinoma cells in agar. Cancer Res 38: 3438-3444, 1978.
34. Courtenay VD, Selby PJ, Smith IE, Mills, J and Peckham MJ: Growth of human tumour cell colonies from biopsies using two softagar techniques. Br J Cancer 38: 77-81, 1978.
35. Mattox DE and von Hoff DD: In vitro stem cell assay in head and neck squamous cell carcinoma. Amer J Surgery 140: 527-530, 1980.
36. Johns ME: The clonal assay of head and neck tumor cells: Results and clinical correlations, Laryngoscope 92 (Supplement no 28): 1-26, 1982.
37. Mattox DE, von Hoff DD and Harris LL: Human tumor cloning assay in advanced head and neck cancer. Prospective correlative trial. Arch Otolaryngol 109: 724-726, 1983.
38. Shimoyama Y, Kubota T, Watanabe M, Ishibiki K and Abe O: Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to the clonogenic assay. J Surgical Oncol 41: 12-18, 1984.
39. Kern DH and Weisenthal LM: Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposires. J Natl Cancer Inst 82: 582-588, 1990.
40. Schroyens W, Tueni E, Dodion P, Bodecker R, Stoessel F and Klastersky J: Validation of clinical predictive value of in vitro calorimetric chemosensitivity assay in head and neck cancer. European J Cancer 26: 834-838, 1990.
41. Leone LA, Meitner PA, Myers TJ, Grace WR, Gajewski WH, Fingert HJ and Rotman B: Predictive value of the fluorescent cytoprint assay (FCA): A retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy. Cancer Investigation 9: 491-503, 1991.
42. Bellamy WT: Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 44: 690-708, 1942.
43. von Hoff DD: He's not going to talk about in vitro predictive assays again, is he? J Nat Cancer Inst 82: 96-101, 1990.
44. Phillips RM, Bibby NC and Double JA: A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Nat Cancer Inst 82: 1457-1468, 1990.
45. Xu L, Chen Y-T, Huvos AG, Zlotolow IM, Rettig WJ, Old LJ and Garin-Chesa P: Overexpression of p53 protein in squamous cell carcinomas of the head and neck without apparent gene mutations. Diagnostic Molecular Pathology 3: 83-92, 1994.
46. Mineta H, Borg Å, Dictor M, Wahlberg P and Wennerberg, J. Discordance between p53 protein expression and supressor gene mutation in H and squamous cell carcinoma. Eur J Cancer 31A (Suppl.5): 92, 1995,
47. Lavieille JP, Brambilla E, Riva-Lavieille C, Reyt E, Charachon R, and Brambilla C: Immunohistochemical detection of p53 protein in preneoplastic lesions and squamous cell carcinoma of the head and neck. Acta Otolaryngol (Stockh) 115: 334-339, 1995.
48. Bradford C, Zhu S, Wolf GT, Poore J, Fisher J, Beals T, McClatchey KD, Carey TE and Dept of Vet. Aff. Laryngeal Ca. Study Group. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Otolaryngol Head Neck Surg 113: 408-12, 1995.
49. Gallo O, Bianchi S, Giovannucci-Uzzielli M, Santoro R, Lenzi S, Salimbeni C, Abbruzzese M and Alajmo E: p53 oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies. Br J Cancer 71: 1008-12, 1995.
50. Brun E, Erlandsson K, Holmström G, Kjellén E, Ohlsson T, Sandell A, Strand S-E, Tennvall J, Wennerberg J and Wingårdh K: Förändringar av DNA-profil och av 18-FDG-upptag (PET) under tidigt skede av strål-/cytostatikabehandlaing vid avancerad ÖNH-cancer (abstract). Hygiea 103: 289, 1994.
51. Reisser C, Haberkorn U, Dimitrakopoulou-Strauss A, Seifert E and Strauss LG: Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg 121: 272-6, 1995.
52. McNally NJ: Can cell kinetic parameters predict the response of tumours to radiotherapy. Int J Radiat Biol 56: 777-786, 1989.
53. Hendry JH, West CML, Moore JV and Potten CS: Tumour stem cells: the relevance of predictive assays for tumour control after radiotherapy. Radiotherapy and Oncology 30: 11-16, 1994.
54. Fertil B and Malaise EP: Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys 7:621-9, 1981.
55. Deacon J, Peckham MJ and Steel GG: The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 2: 317-23, 1984.
56. Fertil B and Malaise, E. P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 11: 1699-1707, 1985.
57. Brock WA, Baker FLand Peters LJ: Radiosensitivity of human head and neck squamous cell carcinomas in primary culture and its potential as a predictive assay of tumor radiocurability. Int J Radiat Biol 56: 751-760, 1989.
58. Brock WA, Baker FL, Wike JL, Sivon SL and Peters LJ: Cellular radiosensitivity of primary head and neck squamous cell carcinomas and local tumor control. Int J Radiation Oncology Biol Phys 18: 1283-1286, 1990.
59. Girinsky T, Lubin R, Pignon JP, Chavaudra N, Gazeau J, Dubray B, and Cosset JM: Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinomas: Preliminary correlations with local control and overall survival. Int J Radiation Oncology Biol Phys 25: 3-7, 1992.
60. West CML, Davidson SE, Roberts SA and Hunter RD: Intrinsic radioscnsitivity and the prediction of patient response to radiotherapy for carcinoma of the cervix. Br J Cancer 68: 819-823, 1993.
61. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E and Weichselbaum RR: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines Cancer Res 53: 3667-3669, 1993.
62. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
63. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, and Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
64. Begg AC, McNally NJ, Shrieve DC and Karcher RA: method to measure the duration of DNA synthesis ant the potential doubling time from single sample. Cytometry 6: 620-626, 1985.
65. Begg AC, Hofland I, van Glabbeke M, Bartelink H and Horiot JC: Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC Cooperative trial 22851. Seminars in Radiation Oncology 1: 22-25, 1992.
66. Bourhis J, Wilson G, Wibault P, Bosq J, Chavaudra N, Janot F, Luboinski B, Eschwege F and Malaise EP: In vivo measurement of the potential doubling time by flowcytometry in oropharyngeal cancer treated by conventional raadiotherapy, Int J Radiat Oncol Biol Phys 26: 793-799, 1993.
67. Begg, AC: Prediction of repopulation rates and radiosensitivity in human tumours. Int J Radiat Biol 64: 103-108, 1994.
68. Corvò R, Giaretti W, Sanguineti G, Geido E, Orecchia R, Guenzi M, Margarino G, Bacigalupo A, Garaventa G, Barbieri M and Vitale V: In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol 13: 1843-50, 1995.
69. Terry N, HA and Peters LJ: The predictive value of tumor-cell kinetic parameters in radiotherapy: Considerations regarding data production and analysis (editorial). J Clin Oncology 13: 1833-6, 1995.
70. Bennett MH, Wilson GD, Dische S, Saunders MI, Martindale CA, Robinson BM, O'Halloran AE, Leslie MD and Laing JHE: Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck, Br J Cancer 65: 870-8, 1992.
71. Høyer M, Bentzen SM, Salling LN, and Overgaard J: Influence of sampling time on assessment of potential doubling time. Cytometry 16: 144-51, 1994.
72. Fenech M: The cytokinesis-block micronucleus technique: a detailed description on the method and its application to genotoxicity studies in human populations. Mutat Res 285: 35-44, 1993.
73. Garewal HS, Ramsey L, Kaugars G and Boyle J: Clinical experience with the micronucleus assay. J Cell Biochem Suppl 17F: 206-12, 1993.
74. Midander J and Revesz L: The frequency of micronuclei as a measure of cell survival in irradiated cell populations, Int J Radiat Biol 38: 237-242, 1980.
75. Streffer C: Is the micronucleus assay predictive for cellular radiosensitivity? Br J Cancer, Supplement 24: 70-73, 1992.
76. Shibamoto Y, Shibata T, Miyatake S, Oda Y, Manabe T, Ohshio G, Yagi K, Streffer C, Takahashi M and Abe M: Assessment of the proliferative activity and radiosensitivity of human tumours using the cytokinesis-block micronucleus assay. Br J Cancer 70: 67-71, 1994.
77. Weidner N: Tumor angiogenesis: Review of current applications in tumor prognostication. Semin Diagn Pathol 10: 302-313, 1993.
78. Kolstad P: Vascularization, oxygen tension and radiocurability in cancer of the cervix, University of Oslo. Norway, 1964.
79. Delides G, Venizelos J and Revesz L: Vascularization and curability of stage III and IV nasopharyngeal tumors. J Cancer Res Clin Oncol 114: 321-3, 1988.
80. Zätterström UK, Brun E, Willén R, Kjellén E and Wennerberg J: Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head and Neck 17: 312-318, 1995.
81. Browman GP, Wong G, Hodson I, Sathya J, Russell R, McAlpine L, Skingley P and Levine MN: Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. New England J Medicine 328: 159-163, 1993.
82. Nordman E, Joensuu H, Kellokumpu-Lehtinen P, Minn H and Mäntylä M: Is it possible to predict the outcome of radiation therapy of head and neck cancer? Acta Oncologica 29: 521-524, 1990.
83. Jaulerry C, Dubray B, Brunin F, Rodriguez J, Point D, Blaszka B, Asselain B, Mosseri V, Brugere J and Cosset J-M: Prognostic value of tumor regression during radiotherapy for head and neck cancer: A prospective study. Int J Radiation Oncology Biol Phys 33: 271-9, 1995.
84. Lederman, M Radiation therapy in cancer of the larynx. Current concepts in cancer. JAMA 221: 1253-4, 1972.
85. Fazekas JT, Green JP, Vaeth JM and Schroeder AF: Post irradiation induration as a prognosticator. A retrospectiveanalysis of squamous cell carcinomas of the oral cavity and oropharynx. Radiology 102: 409-12, 1972.
86. Barkley HT and Fletcher GH: The significance of residual disease after external irradiation of squamous cell carcinoma of the oropharynx. Radiology 124: 493-5, 1977.
87. Dawes PJDK: The early response of oral, oropharyngeal, hypopharyngeal and laryngeal cancer related to local control and survival. Br J Cancer 41(Suppl. IV): 14-16, 1980.
88. Minn H, Paul R and Ahonen A: Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 29: 1521-5, 1988.
89. Wasson JH, Sox HC, Neff RK and Goldman L: Clinical prediction rules. Applications and methodological standards. New England J Medicine 313: 793-799, 1985.
90. Kosmidis PA: Head and neck cancer. European Cancer News 6: 9-13, 1993.